Centre for Probe Development and Commercialization (CPDC) Appoints New Head of Business Development

November 16, 2018 CPDC

Hamilton, Ontario, November 16, 2018 – The Centre for Probe Development and Commercialization (CPDC) is proud to introduce the new Head of Business Development, Bruno Paquin, PhD.

Bruno comes to us with years of experience in research and development and he brings with him extensive knowledge of scientific operations in life and health sciences, as well as an impressive resume of business development expertise.

“This is a very exciting addition to the CPDC team,” stated Dr. Joe McCann, CEO of CPDC. “Bruno will lead the growth of our radiopharmaceutical imaging products business as well as provide business support to our contract services unit that is focused on regulatory affairs and clinical trial management. With Bruno’s knowledge and expertise, he will play a key role in keeping CPDC at the forefront of the industry.”

Bruno received his PhD in Biochemistry from Université de Montréal before conducting his post-doctoral research at the University of Albany. He became the Laboratory Director at Université de Montréal, Département de Biochimie, where he was responsible for the management and direction of a team of scientists. In 2000, he became the head of the Technology Development Unit at Genizon Biosciences Inc., where he was appointed the Executive Director, Head of Business Development.

In 2010, Bruno became a consultant for Business & Strategy Development in Life Sciences, Genetics and Pharmacogenomics for several organizations, and then went on to become VP of Business Development for Immuni T in Montréal in 2011. He has published extensively, is a named inventor in over 24 patent applications and has presented at international conferences.

Dr. Paquin stated, “I’m proud to become part of such an impressive organization that plays a major role in helping Canadians. I look forward to working alongside Dr. McCann and the rest of the team to extend the reach of CPDC products and services.”

About CPDC
The Centre for Probe Development and Commercialization (CPDC) is a Centre of Excellence for Commercialization and Research (CECR) located at McMaster University in Hamilton, Ontario, Canada. CPDC is a private, not-for-profit company and global leader in the discovery, development and commercialization of next-generation radiopharmaceuticals that was created with the support of multiple stakeholders, including the Networks of Centres of Excellence (NCE), McMaster University and The Ontario Institute for Cancer Research (OICR). Since its foundation in 2008, CPDC has established a pipeline of products along with a robust and reliable global supply of innovative diagnostic and therapeutic radiopharmaceuticals used daily for the detection and treatment of human diseases such as cancer. For more information about CPDC, please visit: www.imagingprobes.ca.

Contacts
Centre for Probe Development and Commercialization
Angela Laurentani, 905 525-9140, ext. 21212
cpdc@imagingprobes.ca

More news from CPDC

CPDC Announces First Patient Dosed in a Phase 3 Clinical Trial of a Prostate Cancer Diagnostic Imaging Product, [18F]PSMA-1007

Hamilton, Ontario, February 24, 2021 – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, is announcing today that the first patient has been dosed and imaged in a Phase 3 trial for [18F]PSMA-1007. This diagnostic imaging product is a positron-emitting tomography (PET) agent that

CARI Blog #2: Discover the Medical Isotope & Radiopharmaceutical Landscape in Canada

Did you know that Canada has been a global leader in the research, development and production of medical isotopes as well as radiopharmaceuticals for more than 60 years? Many people are unaware of Canadian role in this industry. However, several medical applications that are used widely today stemmed from Canadian nuclear isotope programs where much

POINT Biopharma signs exclusive license agreement with CanProbe for the commercialization of a neuroendocrine tumor treatment

January 12th, 2021 – TORONTO, CANADA – POINT Biopharma Inc. (POINT), a radiopharmaceutical company dedicated to bringing the many benefits of precision radioligand therapy to cancer patients, today announced that it has signed a licensing and commercialization agreement with CanProbe for exclusive rights to Lutetium – 177 Octreotate (Lu-DOTATATE) for the treatment of neuroendocrine cancer.

For more information contact us at: